A Phase I Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer.

Richard D KimElaine TanEmily WangAmit MahipalDung-Tsa ChenBiwei CaoFadzai MasawiCindy MachadoJames YuDae Won Kim

Published in: The oncologist (2020)

Trametinib and sorafenib can be safely administered up to trametinib 1.5 mg daily and sorafenib 200 mg twice a day with limited anticancer activity in advanced HCC.

Keyphrases

papillary thyroid
clinical trial
physical activity
phase iii
randomized controlled trial
squamous cell carcinoma
young adults
childhood cancer